41
USTEKINUMAB OPEN-LABEL INDUCTION AND RANDOMIZED BLINDED MAINTENANCE THERAPY IN PEDIATRIC PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: THE PHASE 3 UNITI JR STUDY
Date
May 3, 2025
Explore related products in the following collection:
